Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

Background/Aims Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of this study was to identify clinical factors affect...

Full description

Bibliographic Details
Main Authors: Chan-Young Ock, Shin-Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Format: Article
Language:English
Published: The Korean Association of Internal Medicine 2019-09-01
Series:The Korean Journal of Internal Medicine
Subjects:
crizotinib
anaplastic lymphoma kinase
lung neoplasms
disease-free survival
proportional hazards models
Online Access:http://www.kjim.org/upload/pdf/kjim-2018-011.pdf

Internet

http://www.kjim.org/upload/pdf/kjim-2018-011.pdf

Similar Items